CBSA celebrates policy victories for Colorado’s life sciences community and America’s innovators, scientists, and entrepreneurs. Congress reauthorized critical SBIR/STTR and User Fee programs. Without action, they were set to expire at the end of September.
On September 29, the U.S. House of Representatives passed legislation to reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
Additionally, House and Senate lawmakers agreed to a continuing resolution (CR) that would prevent a government shutdown until Congress can work out a longer-term spending bill in mid-December. The CR includes reauthorization of FDA’s prescription, generic, biosimilar, and medical device User Fee programs for another five years. This means the agency will not have to lay off user-fee funded staff. The fees support FDA resources and capacity, offering greater predictability for the industry.
The SBIR/STTR programs are vital for life sciences companies and researchers in Colorado….
Click here to view original post